ǰÑÔ
¸ßѪѹÊÇÌåÑ»·¶¯ÂöѹÔö¸ßµÄÒ»ÖÖ³£¼ûÐÄѪ¹Ü¼²²¡£¬ÓÉ»ùÒòºÍÇéÐζàÒòËØÏ໥×÷ÓÃÒýÆð£¬ÊÇÈ«Çò¹æÄ£ÄÚµÄÖØÖÁ¹«¹²ÎÀÉúÎÊÌ⣬¿É·ÖΪԷ¢ÐÔ¸ßѪѹºÍ¼Ì·¢ÐÔ¸ßѪѹÁ½´óÀà¡£¸ßѪѹ¿ÉÒýÆðÉíÌå¶àÆ÷¹ÙË𺦣¬ÒÔÐÄ¡¢ÄÔ¡¢ÉöΪÖ÷¡£ÓÉÓÚ¸ßѪѹ·¢²¡ÒòËØÖØ´ó£¬ÓÖÊǶàÖÖ¼²²¡µÄΣÏÕÒòËØ£¬Òò´ËÐèÒª²î±ð¶¯ÎïÄ£×ÓÇø·Ö²î±ðÒÅ´«ºÍÇéÐÎÒòËØ£¬ÓÃÓÚÑо¿¸ßѪѹ²¡µÄ·¢²¡»úÖÆÒÔ¼°ºÍÆäËû¼²²¡µÄ¹ØÏµ£¬ÕÒµ½Ô¤·ÀºÍÖÎÁƵÄÒªÁì¡£
¸ßѪѹ¶¯ÎïÄ£×ÓÆ¾Ö¤ÔìÄ£·½·¨¿ÉÒÔ·ÖΪÒÅ´«ÐÔÄ£×ӺͷÇÒÅ´«ÐÔÄ£×ÓÒÅ´«ÐÔÄ£×ÓÓеÄÊÇͨ¹ý½ü½»Ïµ×ÌÉúºÍ±íÐÍɸѡ£¬½¨Éè×ÔȻͻ±äµÄƷϵ£¬¶àÊÇ´óÊóÄ£×Ó¡£ÁíÒ»·½Ãæ¿ÉÒÔʹÓûùÒò¹¤³ÌÊÖÒÕ£¬Í¨¹ý»ùÒòÐÞÊλñµÃ¸ßѪѹģ×Ó¡£ÓÉÓÚСÊóµÄת»ùÒòºÍ»ùÒòÇóýÊÖÒյijÉÊ죬ÕâÀàÄ£×ÓÒÔСÊóÄ£×ÓΪÖ÷¡£·ÇÒÅ´«ÐÔÄ£×Ó¿ÉÒÔͨ¹ýÉöѪ¹ÜÊÖÊõ»ò¼¤ËØ¡¢Òûʳ¡¢Ò©Îï¡¢Ó¦¼¤µÈÓÕµ¼·½·¨ÖƱ¸¡£¶øÒÅ´«ÐÔÄ£×ӺͷÇÒÅ´«ÐÔÄ£×ÓµÄÏ໥ÍŽᣬ¸ü¿ÉÒÔÑо¿»ùÒòºÍÇéÐÎÒòËØµÄÏ໥ӰÏì¡£½øÒ»²½ÍŽáÆäËûÏà¹Ø¼²²¡»ò æé¹ÙËðº¦Ä£×Ó£¬ÀýÈç¸ß֬Ѫ֢ģ×Ó¡¢ÒȵºËضԿ¹Ä£×Ó¡¢·ÊÅÖÄ£×ӵȣ¬Îª¸ßѪѹºÍÆäËû¼²²¡Ï໥¹ØÏµµÄÑо¿ÒÔ¼°Ïà¹ØÖÎÁÆÒªÁìµÄ¡¢Ñо¿ÌṩºÜºÃµÄÑо¿¹¤¾ß¡£×ÜÖ®£¬ÏÖÔÚÑо¿¸ßѪѹ½ÓÄɶàÒòËØµÄ¶¯ÎïÄ£×ӽ϶࣬¶¯ÎïÖÖÀàÒÔСÊó¡¢´óÊóÄ£×ÓΪÖ÷¡£Ëæ×Å´óÊóµÄ»ùÒòÇóýºÍת»ùÒòÊÖÒÕµÄÖð²½½¨ÉèÆðÀ´£¬ÆäÔÚ¸ßѪѹģ×ÓÖÐÓ¦ÓõÄÔöÌí½«Öð²½µØÌ滻СÊó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
Ëæ×ÅÒÅ´«Ñ§ºÍ·Ö×ÓÉúÎïѧÑо¿Ï£Íû£¬µ¥»ùÒòÍ»±äÒýÆð¸ßѪѹµÄ»ùÒòÒÑÖªµÄÓÐÈ©¹ÌͪºÏ³Éø¡¢11βôÇ»¯Ã¸¡¢11βôÇÀà¹Ì´¼ÍÑÇâø(11βOHSD)¡¢ÉÏÆ¤Ï¸°ûÄÆÍ¨µÀ(epithelial sodium channel, ENaC)µÈ»ùÒò¡£¶ø¸ßѪѹµÄ²¡Àí»úÖÆÑо¿Ò²ÌáÐÑÁËÔ·¢ÐÔ¸ßѪѹºòÑ¡»ùÒò£¬°üÀ¨Ñª¹ÜÖ÷ÒªËØÔ(angiotensinogen,AGT£©Ñª¹ÜÖ÷ÒªËØ×ª»¯Ã¸(angiotensin converting enzyme, ACE)¡¢ÉöËØ¡¢Ñª¹ÜÖ÷ÒªËØ¢ò1ÐÍÊÜÌå(Type 1 angiotensin ¢ò receptor, AT2R1£©ÄÚÆ¤ËØ¡¢ÐÄÄÆËØ¡¢β2-ÉöÉÏÏÙËØÊÜÌå¡¢α-adducin¡¢GÂѰ×β3Ñǵ¥Î»¡¢¶ù²è·Ó°·´úлÓйصÄø¼°ÆäÊÜÌå¡£ÆäËûǰÏßÏÙËØÊÜÌå¡¢B2»º¼¤·ô(B2 Bradykinin)ÊÜÌå¡¢Na+/H+תÔËÌå(Na+/H+ exchanger,NHE)¡¢ÌÇÖ¬´úл£¨ÈçÒȵºËØ£©Ïà¹Ø»ùÒòÒ²±»ÒÔΪÊǸßѪѹÒ׸лùÒò¡£ÒÔÉÏ»ùÒòµÄת»ùÒòºÍ»ùÒòÇóýСÊóÄ£×Ó»ù±¾É϶¼ÒÑ¾ÖÆ±¸£¬Ó¦ÓÃÓÚÄ£ÄâÈËÀàÖÖÖÖÏìÓ¦ÀàÐ͵ĸßѪѹ¼²²¡Ñо¿¡£´óÊóÄ£×ÓÖУ¬TGR (mREN2)27ÊÇ×îÓдú±íÐÔµÄת»ùÒò´óÊó¸ßѪѹģ×Ó¡£
¡¾Ä£×ÓÌØµã¡¿£º
»ùÒòÐÞÊθßѪѹ¶¯ÎïÄ£×Ó×î»ù±¾µÄÌØµãÊǾßÓкÜÊÇÃ÷È·µÄÒÅ´«Ö²¡ÒòËØ£¬Òò´Ë²¡Àí»úÖÆÃ÷È·£¬±íÐÍÎȹ̣¬´ú±íÁËij¸ö»ùÒò»òѪѹµ÷¿ØÍ¾¾¶ÒýÆðµÄ¸ßѪѹµÄÌØÕ÷¡£
¡¾Ä£×ÓȪԴ¡¿£º
´ó´ó¶¼»ùÒòÐÞÊÎСÊó¿ÉÒÔ´ÓJacksonʵÑéÊÒ¡¢MMRRC¹«Ë¾»ñµÃ¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
ת»ùÒòºÍ»ùÒòÇóýÄ£×Ó²»µ«¿ÉÒÔÄ£ÄâÈËÀà¸ßѪѹ²¡£¬Ó¦ÓÃÓÚ»ù´¡ºÍÒ©ÎïÑо¿£¬²¢ÇÒ¿ÉÒÔÑо¿¸ßѪѹµÄ·¢²¡»úÖÆºÍÒ©Îï°Ðµã£¬Ñо¿»ùÒòÖ®¼äÒÔ¼°»ùÒòÓëÇéÐÎÒòËØµÄÏ໥¹ØÏµ¡£
²Î¿¼ÎÄÏ×£º
1.ÖÓº½º££¬·ëÓ¢¿£®ÂýÐÔ¸´ºÏÓ¦¼¤ÓÕ·¢¸ßѪѹ¶¯ÎïÄ£×ÓµÄÖÆ±¸£®ÏÖ´úÒ½Ò©ÎÀÉú£¬2010, 26 (23):3523-3525
2.DiBona GF. Sympathetic nervous system and hypertension. Hypertension,2013, 61 (3):556-560
3.Domas WC.Silva ME. An.imal models for tl1e study of arterial hypertension. J Biosci,2011, 36 (4):731-737
4.Drenjancevic-Peric 1, Jelakovic B, Lombard J H, et al. High-salt diet and hypertension: focus on the renin- angiolensin system. Kirlney Blood Press Res,201L,34(1): 1-11
5.Harrison M, Maresso K, Broeckel U. Genetic detenn.inants of hype.rlens.ion:an update. Curr Hyperlens Rep, 2008, 10 (6):488-495
6.Lerman LO,Chade AR,Sica V.el al. Animal models of hypertension:an ove.rview. J Lab Clin Med,2005, 146(3): 160-173
7.Li J, LaMarca B,Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine pe.rfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol,2012,303(1): Hl-8
8.Madero M,Perez-Pozo SE,Jalal D,et al. Dietary fructoseand hypertension. Curr Hyperteos Rep,2011,13(l):29-35
9.O'Toole TE, Conklin DJ, Bhatnagar A. Environmental risk factors for heart disease. Rev Environ Health, 2008, 23(3): 167-202
10.Queisser N,Schupp N. Aldosterooe,oxidative stress,and NF-kB activation i.n hypertension-related cardiovascular and renal diseases. Free Radie Biol Med,2012,53(2):314-327
11.Torok J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res, 2008, 57 (6): 813-825